GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QuidelOrtho Corp (NAS:QDEL) » Definitions » Cash Flow from Operations

QuidelOrtho (QuidelOrtho) Cash Flow from Operations : $91 Mil (TTM As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is QuidelOrtho Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2024, QuidelOrtho's Net Income From Continuing Operations was $-1,706 Mil. Its Depreciation, Depletion and Amortization was $115 Mil. Its Change In Working Capital was $-86 Mil. Its cash flow from deferred tax was $-74 Mil. Its Cash from Discontinued Operating Activities was $0 Mil. Its Asset Impairment Charge was $1,744 Mil. Its Stock Based Compensation was $9 Mil. And its Cash Flow from Others was $-2 Mil. In all, QuidelOrtho's Cash Flow from Operations for the three months ended in Mar. 2024 was $-1 Mil.


QuidelOrtho Cash Flow from Operations Historical Data

The historical data trend for QuidelOrtho's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QuidelOrtho Cash Flow from Operations Chart

QuidelOrtho Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 134.49 629.76 805.90 885.30 280.20

QuidelOrtho Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 188.90 -30.60 41.50 80.40 -0.70

QuidelOrtho Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

QuidelOrtho's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

QuidelOrtho's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


QuidelOrtho  (NAS:QDEL) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

QuidelOrtho's net income from continuing operations for the three months ended in Mar. 2024 was $-1,706 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

QuidelOrtho's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $115 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

QuidelOrtho's change in working capital for the three months ended in Mar. 2024 was $-86 Mil. It means QuidelOrtho's working capital declined by $86 Mil from Dec. 2023 to Mar. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

QuidelOrtho's cash flow from deferred tax for the three months ended in Mar. 2024 was $-74 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

QuidelOrtho's cash from discontinued operating Activities for the three months ended in Mar. 2024 was $0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

QuidelOrtho's asset impairment charge for the three months ended in Mar. 2024 was $1,744 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

QuidelOrtho's stock based compensation for the three months ended in Mar. 2024 was $9 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

QuidelOrtho's cash flow from others for the three months ended in Mar. 2024 was $-2 Mil.


QuidelOrtho Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of QuidelOrtho's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


QuidelOrtho (QuidelOrtho) Business Description

Traded in Other Exchanges
Address
9975 Summers Ridge Road, San Diego, CA, USA, 92121
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make better decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
Executives
Louise Brandy officer: SVP, Chief Information Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Patrick Klein officer: Chief Administrative Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Christopher M Smith director 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Edward L. Michael director 618 SHERIDAN SQUARE, EVANSTON IL 60202
William J. Ferenczy officer: SVP, Cardio/Metabolic Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Werner Kroll officer: SVP, Research and Development 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Kenneth F Buechler director
Robert R. Schmidt director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tamara A. Ranalli officer: SVP, Molecular Bus. Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Stephen H. Wise director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Robert Joseph Bujarski officer: See Remarks C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Wilkins Joseph D Jr. director 82414 PUCCINI DRIVE, INDIO CA 92203
Michelle A. Hodges officer: SVP, General Counsel 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Douglas C Bryant director, officer: Chairman & CEO C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Joseph M Busky officer: Chief Financial Officer 1717 DEERFIELD ROAD, DEERFIELD IL 60015